Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 19/20 | 0.85 |
| ▸ | ALK | Q9UM73 | 14/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25566031 | 0.92 | NTRK1 (1.00) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25567160 | 0.85 | NTRK1 (0.88) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565929 | 0.85 | NTRK1 (0.86) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25575340 | 0.82 | NTRK1 (0.81) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25567185 | 0.81 | NTRK1 (0.81) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565688 | 0.81 | NTRK1 (0.69) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565691 | 0.81 | NTRK1 (0.72) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565685 | 0.80 | NTRK1 (0.71) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565684 | 0.79 | NTRK1 (0.69) | NTRK1ALKJAK2PTK2 | |
| SCHEMBL25565953 | 0.77 | NTRK1 (1.00) | NTRK1ALKJAK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | NTRK1 67/4885ALK 1/4885JAK2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.